Spray Drying of Amorphous Dispersions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Spray Drying of Amorphous Dispersions
Fundamental approaches to performance, stability and manufacture


Pharmaceutical Technology Europe
Volume 24, Issue 9

Spray drying is a key process for manufacturing amorphous dispersions because of its breadth of applicability. The wide range of potential atomization techniques and controllable drying kinetics enables amorphous spray-dried dispersions (SDDs) to be produced from a wide variety of active pharmaceutical ingredients (APIs). Moreover, spray drying is a continuous, efficient, and well-characterized process that can be easily scaled up from development to pilot to production scale. The use of spray drying for pharmaceutical applications is important because amorphous dispersions are key delivery technologies for increasing the solubility of BCS Class II and IV drugs, which represent more than 50% of the compounds in pharmaceutical company pipelines.


Figure 1: Spray drying process and key amorphous dispersion attributes.
Bend Research, a leader in the production of amorphous dispersions for pharmaceutical applications, has devoted a substantial amount of work to the application of fundamental engineering principles to the spray drying of amorphous dispersions. Application of fundamental knowledge has made it possible to obtain spray-dried amorphous dispersions with the desired stability and performance attributes, smooth process scale-up, and downstream manufacturability. An overview of the process and product is shown in Figure 1.

Performance

The spray drying process is amenable to the manufacture of amorphous dispersions across a wide range of API physicochemical properties. Mechanistic understanding of the dissolution mechanism is critical during formulation selection. Dissolution of the primary solid dispersion particle to free drug or high-activity drug species is necessary to enchance the bioavailability of the amorphous solid.

To increase the efficiency and robustness of formulation selection, "guidance maps" are used that account for key API properties related to physical stability and performance. Drug loading and polymer selection can be efficiently optimized to achieve the desired performance attributes of the dispersion (1). The process space is then selected to provide a robust manufacturing window.

Stability

Physical stability during spray drying is maintained through the rapid drying kinetics of high-surface-area droplets. Rapid quenching of droplets to achieve a low mobility state, facilitated by use of a high-Tg polymer, is critical to achieving an amorphous dispersion. Atomization and drying conditions are both optimized to ensure a reproducible, robust process that achieves a molecular dispersion and promotes physical stability during in-process hold times.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here